Position in CELC
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$16,127,525
+$11,955,302 QoQ
Shares Held
141,296
+237.8% QoQ
Ownership
0.290%
of shares outstanding
% of Portfolio
3.48%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in CELC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Atle Fund Management AB holds $202,705,517 across 20 Biotechnology names. CELC ranks #4 (8.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
617,245 | $60,027,076 | |
| 2 | BCAX |
Bicara Therapeutics Inc.
|
1,169,634 | $23,264,020 | |
| 3 | MIRM |
Mirum Pharmaceuticals, Inc.
|
195,768 | $18,085,047 | |
| 4 | CELC |
Celcuity Inc.
This page
|
141,296 | $16,127,525 | |
| 5 | INSM |
INSMED Inc
|
97,438 | $15,933,061 | |
| 6 | ONC |
BeOne Medicines Ltd.
|
41,717 | $12,388,697 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
22,984 | $10,263,275 | |
| 8 | KRYS |
Krystal Biotech, Inc.
|
37,579 | $9,707,407 |
All Filings in CELC
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $16,127,525 | 141,296 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $4,172,223 | 41,831 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $1,835,555 | 37,157 | Shares | Sole | 2025-11-04 | |
| No filing history on record for this holder in this stock. | ||||||